normal human dermal nhd fibroblast cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC normal human dermal nhd fibroblast cell lines
    (A) Schematic graph illustrating the timeline for the culture and TGF-β1 treatment of dcSSc-isolated fibroblasts, matched healthy-isolated fibroblasts, and Normal Human Dermal <t>(NHD)</t> <t>fibroblast</t> cells. (B) RUNX1 expression rate in samples treated with TGF-β1 (in red) vs. control for the 24 hours after exposure. (C) Volcano plot of differentially expressed analysis of the two SSc-isolated fibroblast lines at 12 hours after exposure vs. the baseline. (D) The pathway analysis of Reactome gene sets shows the biological pathways and processes that are significantly represented within top DEG genes of SSc-isolated fibroblast lines 12 hours after TGF-β1 treatment vs. the baseline. (E) Fold change expression of TGF-β1 and CBFB in TGF-β1-induced SSc fibroblasts treated with Ro5-3335 ( RUNX1 inhibitor), compared to control. (F) Proliferation curve of NHD fibroblasts in the presence and absence of Ro5-3335. (G–H) The 3D collagen contraction assays, fixed (G) and floating ( H ) models, of NHD fibroblasts treated with Ro5-3335. SIS3 (SMAD3 inhibitor) was used as positive control that significantly eliminates the contraction ability of fibroblasts. (Student’s t-test P- value: **0.001–0.01, ****<0.0001 in GraphPad Prism v9)
    Normal Human Dermal Nhd Fibroblast Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/normal human dermal nhd fibroblast cell lines/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    normal human dermal nhd fibroblast cell lines - by Bioz Stars, 2024-05
    86/100 stars

    Images

    1) Product Images from "RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis"

    Article Title: RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis

    Journal: bioRxiv

    doi: 10.1101/2024.04.03.587966

    (A) Schematic graph illustrating the timeline for the culture and TGF-β1 treatment of dcSSc-isolated fibroblasts, matched healthy-isolated fibroblasts, and Normal Human Dermal (NHD) fibroblast cells. (B) RUNX1 expression rate in samples treated with TGF-β1 (in red) vs. control for the 24 hours after exposure. (C) Volcano plot of differentially expressed analysis of the two SSc-isolated fibroblast lines at 12 hours after exposure vs. the baseline. (D) The pathway analysis of Reactome gene sets shows the biological pathways and processes that are significantly represented within top DEG genes of SSc-isolated fibroblast lines 12 hours after TGF-β1 treatment vs. the baseline. (E) Fold change expression of TGF-β1 and CBFB in TGF-β1-induced SSc fibroblasts treated with Ro5-3335 ( RUNX1 inhibitor), compared to control. (F) Proliferation curve of NHD fibroblasts in the presence and absence of Ro5-3335. (G–H) The 3D collagen contraction assays, fixed (G) and floating ( H ) models, of NHD fibroblasts treated with Ro5-3335. SIS3 (SMAD3 inhibitor) was used as positive control that significantly eliminates the contraction ability of fibroblasts. (Student’s t-test P- value: **0.001–0.01, ****<0.0001 in GraphPad Prism v9)
    Figure Legend Snippet: (A) Schematic graph illustrating the timeline for the culture and TGF-β1 treatment of dcSSc-isolated fibroblasts, matched healthy-isolated fibroblasts, and Normal Human Dermal (NHD) fibroblast cells. (B) RUNX1 expression rate in samples treated with TGF-β1 (in red) vs. control for the 24 hours after exposure. (C) Volcano plot of differentially expressed analysis of the two SSc-isolated fibroblast lines at 12 hours after exposure vs. the baseline. (D) The pathway analysis of Reactome gene sets shows the biological pathways and processes that are significantly represented within top DEG genes of SSc-isolated fibroblast lines 12 hours after TGF-β1 treatment vs. the baseline. (E) Fold change expression of TGF-β1 and CBFB in TGF-β1-induced SSc fibroblasts treated with Ro5-3335 ( RUNX1 inhibitor), compared to control. (F) Proliferation curve of NHD fibroblasts in the presence and absence of Ro5-3335. (G–H) The 3D collagen contraction assays, fixed (G) and floating ( H ) models, of NHD fibroblasts treated with Ro5-3335. SIS3 (SMAD3 inhibitor) was used as positive control that significantly eliminates the contraction ability of fibroblasts. (Student’s t-test P- value: **0.001–0.01, ****<0.0001 in GraphPad Prism v9)

    Techniques Used: Isolation, Expressing, Positive Control

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    ATCC normal human dermal nhd fibroblast cell lines
    (A) Schematic graph illustrating the timeline for the culture and TGF-β1 treatment of dcSSc-isolated fibroblasts, matched healthy-isolated fibroblasts, and Normal Human Dermal <t>(NHD)</t> <t>fibroblast</t> cells. (B) RUNX1 expression rate in samples treated with TGF-β1 (in red) vs. control for the 24 hours after exposure. (C) Volcano plot of differentially expressed analysis of the two SSc-isolated fibroblast lines at 12 hours after exposure vs. the baseline. (D) The pathway analysis of Reactome gene sets shows the biological pathways and processes that are significantly represented within top DEG genes of SSc-isolated fibroblast lines 12 hours after TGF-β1 treatment vs. the baseline. (E) Fold change expression of TGF-β1 and CBFB in TGF-β1-induced SSc fibroblasts treated with Ro5-3335 ( RUNX1 inhibitor), compared to control. (F) Proliferation curve of NHD fibroblasts in the presence and absence of Ro5-3335. (G–H) The 3D collagen contraction assays, fixed (G) and floating ( H ) models, of NHD fibroblasts treated with Ro5-3335. SIS3 (SMAD3 inhibitor) was used as positive control that significantly eliminates the contraction ability of fibroblasts. (Student’s t-test P- value: **0.001–0.01, ****<0.0001 in GraphPad Prism v9)
    Normal Human Dermal Nhd Fibroblast Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/normal human dermal nhd fibroblast cell lines/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    normal human dermal nhd fibroblast cell lines - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    Image Search Results


    (A) Schematic graph illustrating the timeline for the culture and TGF-β1 treatment of dcSSc-isolated fibroblasts, matched healthy-isolated fibroblasts, and Normal Human Dermal (NHD) fibroblast cells. (B) RUNX1 expression rate in samples treated with TGF-β1 (in red) vs. control for the 24 hours after exposure. (C) Volcano plot of differentially expressed analysis of the two SSc-isolated fibroblast lines at 12 hours after exposure vs. the baseline. (D) The pathway analysis of Reactome gene sets shows the biological pathways and processes that are significantly represented within top DEG genes of SSc-isolated fibroblast lines 12 hours after TGF-β1 treatment vs. the baseline. (E) Fold change expression of TGF-β1 and CBFB in TGF-β1-induced SSc fibroblasts treated with Ro5-3335 ( RUNX1 inhibitor), compared to control. (F) Proliferation curve of NHD fibroblasts in the presence and absence of Ro5-3335. (G–H) The 3D collagen contraction assays, fixed (G) and floating ( H ) models, of NHD fibroblasts treated with Ro5-3335. SIS3 (SMAD3 inhibitor) was used as positive control that significantly eliminates the contraction ability of fibroblasts. (Student’s t-test P- value: **0.001–0.01, ****<0.0001 in GraphPad Prism v9)

    Journal: bioRxiv

    Article Title: RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis

    doi: 10.1101/2024.04.03.587966

    Figure Lengend Snippet: (A) Schematic graph illustrating the timeline for the culture and TGF-β1 treatment of dcSSc-isolated fibroblasts, matched healthy-isolated fibroblasts, and Normal Human Dermal (NHD) fibroblast cells. (B) RUNX1 expression rate in samples treated with TGF-β1 (in red) vs. control for the 24 hours after exposure. (C) Volcano plot of differentially expressed analysis of the two SSc-isolated fibroblast lines at 12 hours after exposure vs. the baseline. (D) The pathway analysis of Reactome gene sets shows the biological pathways and processes that are significantly represented within top DEG genes of SSc-isolated fibroblast lines 12 hours after TGF-β1 treatment vs. the baseline. (E) Fold change expression of TGF-β1 and CBFB in TGF-β1-induced SSc fibroblasts treated with Ro5-3335 ( RUNX1 inhibitor), compared to control. (F) Proliferation curve of NHD fibroblasts in the presence and absence of Ro5-3335. (G–H) The 3D collagen contraction assays, fixed (G) and floating ( H ) models, of NHD fibroblasts treated with Ro5-3335. SIS3 (SMAD3 inhibitor) was used as positive control that significantly eliminates the contraction ability of fibroblasts. (Student’s t-test P- value: **0.001–0.01, ****<0.0001 in GraphPad Prism v9)

    Article Snippet: We analyzed a DNA microarray dataset previously generated by our lab, consisting of two independent SSc fibroblasts, one healthy control fibroblast isolated in parallel, and one normal human dermal (NHD) fibroblast cell lines obtained from ATCC.

    Techniques: Isolation, Expressing, Positive Control